The 8 most recent market catalysts affecting $SBRA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23
Barclays analyst Richard Hightower maintained an 'Equal-Weight' rating on Sabra Health Care REIT (SBRA) but raised the price target from $21 to $23. This action suggests that while…
Aug 3, 2026
Corporate Catalyst
Bearish
Impact 75
Sabra Health Care REIT Lowers FY2026 FFO Guidance from $1.55-$1.59 to $1.53-$1.55 vs $1.55 Est
Sabra Health Care REIT (SBRA) announced a reduction in its FY2026 FFO guidance, moving from an initial range of $1.55-$1.59 to a new range of $1.53-$1.55. This revised outlook fall…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 75
Sabra Health Care REIT Q2 FFO $0.39, Inline, Sales $235.866M Beat $219.689M Estimate
Sabra Health Care REIT (SBRA) announced its Q2 earnings, with Funds From Operations (FFO) meeting analyst expectations at $0.39 per share. More notably, the company's sales signifi…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 60
Truist Securities Maintains Buy on Sabra Health Care REIT, Raises Price Target to $24
Truist Securities analyst Michael Lewis has raised the price target for Sabra Health Care REIT (SBRA) from $22 to $24 while maintaining a 'Buy' rating. This upgrade in price target…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on Sabra Health Care REIT, Raises Price Target to $25
Citizens analyst Aaron Hecht has updated their coverage on Sabra Health Care REIT (SBRA), maintaining a 'Market Outperform' rating and raising the price target from $23 to $25. Thi…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 75
Sabra Health Care REIT shares are trading higher after the company updated its FY2026 guidance ranges.
The updated FY2026 guidance ranges for Sabra Health Care REIT (SBRA) are a significant positive catalyst, directly impacting its stock price. Improved guidance typically signals ma…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 75
Sabra Sees FY26 Net Income Of $0.37-$0.39, FFO Of $1.12-$1.14, Normalized FFO Of $1.53-$1.55, AFFO Of $1.58-$1.60 And Normalized AFFO Of $1.59-$1.61
Sabra Health Care REIT announced a significant business update, including the successful re-tenanting of 26 properties previously leased to Avamere, resulting in a nearly 30% incre…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.